In the BioHarmony Drug Report Database

"Preview" Icon

Miglustat

Zavesca (miglustat) is a small molecule pharmaceutical. Miglustat was first approved as Zavesca on 2002-11-20. It is used to treat gaucher disease in the USA. It has been approved in Europe to treat gaucher disease and niemann-pick diseases. The pharmaceutical is active against ceramide glucosyltransferase. In addition, it is known to target lysosomal acid glucosylceramidase.

 

Trade Name

 

Zavesca
 

Common Name

 

miglustat
 

ChEMBL ID

 

CHEMBL1029
 

Indication

 

gaucher disease, niemann-pick diseases
 

Drug Class

 

Enzyme inhibitors: glucosyltransferase inhibitors

Image (chem structure or protein)

Miglustat structure rendering